Despite limited evidence of EGFR TKIs providing benefit in a few patients with EGFR mutation-positive NSCLC with BM, a clinical need for novel EGFR TKIs with improved efficacy against BM still exists. This evidence concerns the gene EGFR and non-small cell lung carcinoma.